PCSK9 and cardiovascular disorder: Previously, it was reported that gain-of-function mutations in PCSK9 resulted in autosomal dominant familial hypercholesterolemia (Abifadel et al., 2003), whereas loss-of-function mutations in PCSK9 reduced plasma LDL-C levels and decreased risk of cardiovascular disease (CVD) (Jonathan et al., 2005).